 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «123456» |
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Cabenuva: A breakthrough in HIV/AIDS treatment. (Pubmed Central) - Mar 24, 2023
No abstract available
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Single center experience evaluating and initiating people with HIV on long-acting cabotegravir/rilpivirine. (Pubmed Central) - Feb 27, 2023
Despite novel challenges over half of our cohort initiated LAI CAB/RPV. Evaluating for potential non-nucleoside reverse transcriptase inhibitor resistance is an important part of the workup for LAI CAB/RPV and proviral DNA resistance testing can be an additional tool to identify potential resistance.
- || Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
During discussion at #CROI2023, @joseph_eron asked what kind of evidence would be needed to convince regulators & guidelines committees that the approach is feasible -- & to persuade insurers to cover Cabenuva outside its approved indication? 7/ (Twitter) - Feb 23, 2023
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Enrollment open: CAPRI: A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA (clinicaltrials.gov) - Feb 17, 2023
P3, N=12, Recruiting, Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Evaluating for potential non-nucleoside reverse transcriptase inhibitor resistance is an important part of the workup for LAI CAB/RPV and proviral DNA resistance testing can be an additional tool to identify potential resistance. Not yet recruiting --> Recruiting
- ||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion: Cabenuva Injection Tracking in CHORUS (clinicaltrials.gov) - Feb 15, 2023
P=N/A, N=37, Completed, Sponsor: Epividian
Not yet recruiting --> Recruiting Enrolling by invitation --> Completed
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle income countries. (Pubmed Central) - Feb 13, 2023
Enrolling by invitation --> Completed One in ten treatment na
- Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
SOLAR 12-MONTH RESULTS: RANDOMIZED SWITCH TRIAL OF CAB+RPV LA VS ORAL B/FTC/TAF (Ballroom 1 (Level 5)) - Feb 13, 2023 - Abstract #CROI2023CROI_335;
- bictegravir (GS-9883) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
WEIGHT AND METABOLIC CHANGES WITH CABOTEGRAVIR+RILPIVIRINE LONG-ACTING OR BICTEGRAVIR (Flex A (Level 2)) - Feb 13, 2023 - Abstract #CROI2023CROI_222;
- |||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Enrollment open: IMPALA: Improving HIV-1 Control in Africa With Long Acting Antiretrovirals (clinicaltrials.gov) - Feb 3, 2023
P3b, N=540, Recruiting, Sponsor: MRC/UVRI and LSHTM Uganda Research Unit
One in ten treatment na Not yet recruiting --> Recruiting
- ||| Apretude (cabotegravir extended-release injectable suspension) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
☝️ I wouldn’t do it personally 1 (😉)- We don’t have Apretude (CAB) in 🇨🇦. We only have Cabenuva (CAB + RPV, different bottles, same 📦🤷♂️) 2 (😉)- LEN is not easily available in 🇨🇦, yet…and it will require multi drug R HIV for approval. (1/..) (Twitter) - Jan 11, 2023
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial. (Pubmed Central) - Jan 11, 2023
Results indicated higher intentions to SWI over OLI among HCPs initiating participants on LA ART. A major factor associated with SWI was provider comfort with safety data, reinforcing the role of continued training regarding an SWI approach.
- || Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Adherence: I-TRAINS: Improving Treatment and Retention Adherence in Nontraditional Settings (clinicaltrials.gov) - Dec 28, 2022
P=N/A, N=25, Active, not recruiting, Sponsor: Boston Medical Center
A major factor associated with SWI was provider comfort with safety data, reinforcing the role of continued training regarding an SWI approach. Enrolling by invitation --> Active, not recruiting | N=60 --> 25 | Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
New P1/2 trial: Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age (clinicaltrials.gov) - Dec 21, 2022
P1/2, N=90, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- ||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical: Exactly - 16 weeks suppressed before they were randomised to be switched to CAB/RPV LA (Twitter) - Dec 8, 2022
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
New P3 trial: CAPRI: A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA (clinicaltrials.gov) - Nov 1, 2022
P3, N=12, Not yet recruiting, Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- ||| Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion date, Head-to-Head: SOLAR: A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY (clinicaltrials.gov) - Oct 26, 2022
P3, N=688, Active, not recruiting, Sponsor: ViiV Healthcare
Enrolling by invitation --> Active, not recruiting | N=60 --> 25 | Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023 Trial completion date: Jul 2023 --> Mar 2023
- || Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion date, Trial primary completion date: Implementing Cabenuva in Arkansas HIV Programs (clinicaltrials.gov) - Oct 24, 2022
P=N/A, N=100, Recruiting, Sponsor: University of Arkansas
Trial completion date: Jul 2023 --> Mar 2023 Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Mar 2023 --> Dec 2023
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection. (Pubmed Central) - Oct 9, 2022
Cabotegravir + rilpivirine long-acting provides added value contribution to human immunodeficiency virus-1 management in Spain compared to daily oral single-tablet regimens. Patient Reported Outcomes and therapeutic benefit of cabotegravir + rilpivirine long-acting were highly valued by experts, as the expected benefit in adherence and stigma-related issues would improve overall quality of life for people living with human immunodeficiency virus-1.
- Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Perceptions of cabotegravir and rilpivirine long-acting (CAB+RPV LA) from patients in the CAB+RPV Implementation Study in European Locations (CARISEL) () - Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_249;
PSPs most often received treatment information from their medical provider and reported positive implementation experiences and low pain from CAB+RPV LA injections. These factors may contribute to preference for CAB+RPV LA over oral therapy, perceptions of reduced stigma, and recommendation of CAB+RPV LA to other PLWHIV.
- Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Overcoming barriers and achieving optimal implementation of cabotegravir and rilpivirine long-acting (CAB+RPV LA): staff study participant (SSP) results from the CAB+RPV Implementation Study in European Locations (CARISEL) () - Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_242;
Tips for optimising implementation success include using techniques to minimise injection discomfort and education about the treatment. SSPs recognised that a wide range of patients were appropriate for CAB+RPV LA.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Long-acting combination of cabotegravir plus rilpivirine: a picture of potential eligible HIV-positive individuals from the Italian ARCA cohort () - Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_223;
Less than half of virosuppressed HIV-positive individuals with available GRTs in ARCA cohort were potentially eligible for LA CAB+RPV. They showed a lower zenith viraemia, higher CD4 cell count, a shorter history of HIV infection and exposure to ART compared to those ineligible to LA CAB+RPV.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
HIV-1 RNA blips, low-level viral replication and mean CD4+/CD8+ ratio during phase III/IIIb cabotegravir + rilpivirine long-acting studies up to 152 weeks of therapy () - Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_210;
The proportion of study participants with HIV-1 RNA blips, TND, HIV-1 RNA <2 copies/mL and mean CD4+/CD8+ ratio (proxy for immune-activation) were similar between Q4W CAB+RPV LA and oral three-drug SOC groups through W96 in FLAIR. Although the number of CVFs in FLAIR is low, the presence of HIV-1 RNA blips did not appear to be associated with CVF development through W96.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Implementation of cabotegravir and rilpivirine long-acting (CAB+RPV LA): primary results from the CAB+RPV Implementation Study in European Locations (CARISEL) () - Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_197;
Despite this, high implementation acceptability, appropriateness, and feasibility levels were seen regardless of implementation arm. Implementation measures improved over time.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
The implementation of every-2-months cabotegravir and rilpivirine long-acting injections from the perspective of healthcare providers in the German CARLOS cohort, 6-month outcomes () - Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_158;
The CARLOS cohort provides first insights in HCP perspectives on injectable LA treatment for PLWHIV in a real-world setting in Germany. Although some concerns remained during the first 6 months, the overall feeling about implementing CAB+RPV LA was positive in the majority of HCPs.
- Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Six-month outcomes of every 2-months long-acting cabotegravir and rilpivirine in a real-world setting: effectiveness, adherence to injections and patient-reported outcomes from PLWHIV in the German CARLOS cohort () - Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_127;
CAB+RPV LA shows high rates of maintenance of viral suppression, with low rates of treatment failure in the first 6 months following switch. Despite already high scores on oral ART, the treatment satisfaction score increased statistically significantly on long-acting ART in patients mostly self-selecting CAB+RPV LA.
- | Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J
Journal: An evaluation of long-acting cabotegravir + rilpivirine for the treatment of virologically suppressed adults living with HIV. (Pubmed Central) - Sep 29, 2022
Cabotegravir + rilpivirine is a long-acting injectable that can be used for patients who want to reduce the frequency antiretroviral administration. CAB+RPV allows for virologic suppression with monthly or less often administration, but comes with a significant price point, although injection site reactions may limit utility for many patients.
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South. (Pubmed Central) - Sep 24, 2022
Implementing LAI-ART at a Southern US Ryan White-funded clinic has been challenged by the following: substantial human resource capital to attain drug, administer injections, and support enrolled patients; delayed therapy initiation due to insurance denials; patient ineligibility primarily due to possible RPV resistance; and inability to provide drug regardless of payor source. These barriers may perpetuate disparities in ART access and outcomes among PWH and should be urgently addressed so that LAI-ART can be offered equitably.
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion date: GLACIER: Study Using CABENUVA (clinicaltrials.gov) - Sep 22, 2022
P4, N=120, Recruiting, Sponsor: ViiV Healthcare
These barriers may perpetuate disparities in ART access and outcomes among PWH and should be urgently addressed so that LAI-ART can be offered equitably. Trial completion date: Jul 2023 --> Jan 2024
- || Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
P2b data, Journal: Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials. (Pubmed Central) - Sep 20, 2022
During the COVID-19 pandemic, most trial participants maintained their LA dosing schedules. Flexibility of the LA dosing regimen, with the ability to switch to oral therapy, facilitated continuous ART provision and implementation fidelity.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
New P3 trial: IMPALA: Improving HIV-1 Control in Africa With Long Acting Antiretrovirals (clinicaltrials.gov) - Sep 19, 2022
P3b, N=540, Not yet recruiting, Sponsor: MRC/UVRI and LSHTM Uganda Research Unit
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
CARISEL: A Hybrid III Implementation Effectiveness Study of implementation of Cabotegravir plus Rilpivirine Long Acting (CAB+RPV LA) in EU Health Care Settings; Key Clinical and Implementation Outcomes by Implementation Arm (206) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2582;
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
A Case Series of Low-Level HBV Viremia After Switching to Long-Acting Injectable Cabotegravir/Rilpivirine in Patients with HIV, Hepatitis B Core Antibody Positivity, and Hepatitis B Surface Antigen Negativity (206) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2581;
- Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year (206) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2580;
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
US Healthcare Provider Perspectives on the initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND) (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_1838;
- | Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J
Journal: Frequency of genotypic factors possibly associated with cabotegravir/rilpivirine failure in antiretroviral treatment-naïve and -experienced HIV-1- infected population. (Pubmed Central) - Sep 4, 2022
As subtype A1/A6 becomes more common across real-life cohorts continued subtyping and RAM screening will remain of key importance for LAI treatment implementation. Sequence data from this article have been deposited in GenBank under accession numbers: GU906860, GU906864, GU906871-GU906874, JQ305750-JQ305791, KC409134-KC409222, KM057341-KM057362, KM283892-KM284490, KT340108-KT340205, MZ468643-MZ468894, MZ671788-MZ671823, OP298017-OP302727.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2-Months Is Cost Effective for the Treatment of HIV-1 in Spain (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1701;
Sequence data from this article have been deposited in GenBank under accession numbers: GU906860, GU906864, GU906871-GU906874, JQ305750-JQ305791, KC409134-KC409222, KM057341-KM057362, KM283892-KM284490, KT340108-KT340205, MZ468643-MZ468894, MZ671788-MZ671823, OP298017-OP302727. From the Spanish NHS perspective, CAB+RPV LA Q2M is a cost-effective alternative versus STR daily oral ART, associated with small QALY gains but also with small incremental costs increase.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Potential Healthcare Resource Use and Associated Costs of Every 2-Months Injectable Cabotegravir+Rilpivirine Long-Acting Implementation in the Spanish NHS vs Daily Oral HIV Treatments (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1422;
From the Spanish NHS perspective, CAB+RPV LA Q2M is a cost-effective alternative versus STR daily oral ART, associated with small QALY gains but also with small incremental costs increase. Spanish HCPs anticipated that implementation of CAB+RPV LA in NHS hospitals would not incur in increased HRU-related costs associated to a different patient pathway compared to current daily oral ART, being potentially neutral or even cost-saving.
- || Edurant (rilpivirine) / J&J
Clinical, Observational data, Journal: Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland. (Pubmed Central) - Aug 27, 2022
Data available at present confirm a considerable between-patient variability overall. Based on the growing amount of PK data accumulated during this ongoing study, population pharmacokinetic analysis will characterize individual concentration-time profiles of LAI-CAB/RPV along with their variability in a real-life setting and their association with treatment response and tolerability, thus bringing key data for therapeutic monitoring and precision dosage adjustment of this novel long-acting therapy.
- || Apretude (cabotegravir extended-release injectable suspension) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Could Cabenuva and Apretude Injections Be Self-Administered? @LizHighleyman https://t.co/2DAzmyHBVx #HIV #PrEP #AIDS2022 (Twitter) - Aug 24, 2022
- |||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
As @PaulSaxMD notes in recent @nejm commentary, this approach isn't for everyone -- it exceeds @US_FDA indication for Cabenuva & inconsistent use could lead to drug resistance. But for some it could be a game-changer -- & a life-saver. @ViiV @UCSF @UCSF_HIV_AIDS @ZSFGCare 2/ (Twitter) - Aug 20, 2022
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable HIV Viremia in an Urban HIV Clinic. (Pubmed Central) - Aug 2, 2022
This small demonstration project of LAI-ART in a diverse group of patients with high levels of substance use and marginal housing demonstrated promising early treatment outcomes, including in those with detectable viremia due to adherence challenges. More data on LAI-ART in hard-to-reach populations are needed.
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
FDA event, Journal: Cabenuva: the last FDA-approved drug to treat HIV. (Pubmed Central) - Jul 31, 2022
Cabenuva (cabotegravir/Rilpivirine) is the first LA antiretroviral injectable drug composed of nano-formulation of cabotegravir (CAB) and rilpivirine (RPV)...The injectable LA ART, reduces the number of treatment intake as well as increases adherence especially in patients with HIV-related stigma. Administration of extended-release agents probably minimize the risk of treatment-related toxicity and resistance related to sub-optimal adherence to oral ART, so cabenuva can be suggested as a suitable alternative for HIV infection control in current era.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Safety and effectiveness outcomes from the Carisel study: phase 3b hybrid-3 implementation study integrating cabotegravir + rilpivirine long-acting into European clinical settings () - Jul 2, 2022 - Abstract #AIDS2022AIDS_3900;
Administration of extended-release agents probably minimize the risk of treatment-related toxicity and resistance related to sub-optimal adherence to oral ART, so cabenuva can be suggested as a suitable alternative for HIV infection control in current era. Across diverse European clinical settings and participants, CAB+RPV LA Q2M was well tolerated and highly effective in maintaining virologic suppression with a low rate of virologic failure.
- | lenacapavir (GS CA2) / Gilead
Journal: Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations. (Pubmed Central) - Jul 1, 2022
Novel promising LA anti-HIV agents such as lenacapavir (a capsid-targeting antiviral) and islatravir (EFdA, a nucleoside reverse transcriptase translocation inhibitor) need to be explored as combination therapies...We performed dose-response matrices of these drug combinations in an HIV-1 reporter cell line and subsequently analyzed the data with SynergyFinder Plus, which employs four major drug interaction models: highest single agent, Bliss independence, Loewe additivity, and zero interaction potency. Most of these models predict additive inhibition by the studied drug combinations This work highlights the importance of effective drug combinations in LA-regimens.
- || Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion date, Trial primary completion date: GLACIER: Study Using CABENUVA (clinicaltrials.gov) - Jun 23, 2022
P4, N=120, Recruiting, Sponsor: ViiV Healthcare
Most of these models predict additive inhibition by the studied drug combinations This work highlights the importance of effective drug combinations in LA-regimens. Trial completion date: Oct 2023 --> Jul 2023 | Trial primary completion date: Oct 2023 --> Jul 2023
- ||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical: I think interesting thing is delayed viral rebound. If they can find combos that overcome resistance, there's potential for longer-acting treatment -- though hard to beat every-other-month Cabenuva shots -- & could be component of long-term remission ("functional cure") strategy. (Twitter) - Jun 1, 2022
- || Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Only potential advantage will be dosing interval compared to most therapies other than Cabenuva. Also theoretically bnAbs may augment host immune response (Twitter) - Jun 1, 2022
- ||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Exactly! Or Cabenuva for HIV Rx (Twitter) - May 17, 2022
- ||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion: CUSTOMIZE: Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US) (clinicaltrials.gov) - May 17, 2022
P3, N=115, Completed, Sponsor: ViiV Healthcare
Trial completion date: Oct 2023 --> Jul 2023 | Trial primary completion date: Oct 2023 --> Jul 2023 Active, not recruiting --> Completed
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Single center experience evaluating patients for and initiating long acting cabotegravir/rilpivirine () - May 12, 2022 - Abstract #AIDS2022AIDS_2154;
Those that initiated CAB/RPV were more likely to be on a two drug regimen, possibly due to a lower likelihood of resistance concerns in these patients. The use of archive genotypes provides an additional tool to evaluate for transmitted or polymorphic CAB/RPV resistance that may impact the effectiveness of this regimen.